|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02843347|
Recruitment Status : Recruiting
First Posted : July 25, 2016
Last Update Posted : August 7, 2019
|Condition or disease||Intervention/treatment|
|Anemia, Sickle Cell||Procedure: Blood draw|
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||200 participants|
|Target Follow-Up Duration:||2 Years|
|Official Title:||1503 BMT CTN STRIDE Biorepository|
|Actual Study Start Date :||March 13, 2017|
|Estimated Primary Completion Date :||October 2021|
|Estimated Study Completion Date :||October 2022|
Biorepository substudy participants
Participants from the main study who give consent for the genetic testing substudy.
Procedure: Blood draw
Three tubes of blood (28.5 mL in total) will be obtained at the Baseline Visit. The sample will be stored for future research.
- Genetic variants in persons with sickle cell disease [ Time Frame: Baseline Visit ]A biorepository will be established for future genetic research of sickle cell disease. Blood samples will be drawn from participants at the Baseline Visit and will be stored until analyzed. Analysis will include learning more about the genetics behind complications of sickle cell disease.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02843347
|Contact: Lakshmanan Krishnamurti, MDemail@example.com|
|Principal Investigator:||Lakshmanan Krishnamurti, MD||Emory University|